A Phase II Clinical and Translational Study of MK-2206 in Patients with Metastatic Neuroendocrine Tumors (NETs)

被引：0
|
作者：
Reidy-Lagunes, Diane [1 ,2 ]
Pietanza, M. Catherine [1 ,2 ]
Sega, Michal [1 ,2 ]
Capanu, Marinela [1 ,2 ]
Saltz, Leonard [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
来源：
PANCREAS | 2014年 / 43卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：503 / 503
页数：1
相关论文
共 50 条
  • [21] Phase II Clinical Trial of Pasireotide LAR in Patients with Metastatic Neuroendocrine Tumors
    Cives, M.
    Kunz, P.
    Nguyen, P.
    Jump, H.
    Vilay, K.
    Valone, T.
    Strosberg, J. R.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 270 - 270
  • [22] Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
    B. B. Y. Ma
    B. C. Goh
    W. T. Lim
    E. P. Hui
    E. H. Tan
    G. de Lima Lopes
    K. W. Lo
    L. Li
    H. Loong
    N. R. Foster
    C. Erlichman
    A. D. King
    M. K. M. Kam
    S. F. Leung
    K. C. Chan
    A. T. C. Chan
    Investigational New Drugs, 2015, 33 : 985 - 991
  • [23] A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.
    Han, H. S.
    Swanton, C.
    Janjigian, Y. Y.
    Sutherland, S. C.
    Chandarlapaty, S.
    Lehman, R.
    Hamilton, N.
    Knowles, J.
    Lee, R.
    Yan, L.
    Sullivan, D.
    Hudis, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
    Ma, B. B. Y.
    Goh, B. C.
    Lim, W. T.
    Hui, E. P.
    Tan, E. H.
    Lopes, G. de Lima
    Lo, K. W.
    Li, L.
    Loong, H.
    Foster, N. R.
    Erlichman, C.
    King, A. D.
    Kam, M. K. M.
    Leung, S. F.
    Chan, K. C.
    Chan, A. T. C.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (04) : 985 - 991
  • [25] First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
    Yap, Timothy A.
    Yan, Li
    Patnaik, Amita
    Fearen, Ivy
    Olmos, David
    Papadopoulos, Kyriakos
    Baird, Richard D.
    Delgado, Liliana
    Taylor, Adekemi
    Lupinacci, Lisa
    Riisnaes, Ruth
    Pope, Lorna L.
    Heaton, Simon P.
    Thomas, George
    Garrett, Michelle D.
    Sullivan, Daniel M.
    de Bono, Johann S.
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (35) : 4688 - 4695
  • [26] A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
    Hudis, Clifford
    Swanton, Charles
    Janjigian, Yelena Y.
    Lee, Ray
    Sutherland, Stephanie
    Lehman, Robert
    Chandarlapaty, Sarat
    Hamilton, Nicola
    Gajria, Devika
    Knowles, James
    Shah, Jigna
    Shannon, Keith
    Tetteh, Ernestina
    Sullivan, Daniel M.
    Moreno, Carolina
    Yan, Li
    Han, Hyo Sook
    BREAST CANCER RESEARCH, 2013, 15 (06):
  • [27] A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
    Clifford Hudis
    Charles Swanton
    Yelena Y Janjigian
    Ray Lee
    Stephanie Sutherland
    Robert Lehman
    Sarat Chandarlapaty
    Nicola Hamilton
    Devika Gajria
    James Knowles
    Jigna Shah
    Keith Shannon
    Ernestina Tetteh
    Daniel M Sullivan
    Carolina Moreno
    Li Yan
    Hyo Sook Han
    Breast Cancer Research, 15
  • [28] Phase II study of the oral AKT inhibitor, MK-2206, for acute myeloid leukemia (AML) in second relapse.
    Konopleva, Marina Y.
    Walter, Roland B.
    Faderl, Stefan
    Jabbour, Elias
    Zeng, Zhihong
    Borthakur, Gautam
    Ruvolo, Peter
    Huang, Xuelin
    Kadia, Tapan
    Feliu, Jennie
    Burger, Jan A.
    Andreeff, Michael
    Liu, Wenbin
    Kornblau, Steven M.
    Baggerly, Keith
    Estey, Elihu
    Kantarjian, Hagop
    CANCER RESEARCH, 2013, 73 (08)
  • [29] A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma.(NCI 8727).
    Jonasch, E.
    Lara, P.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma
    Jonasch, E.
    Hasanov, E.
    Corn, P. G.
    Moss, T.
    Shaw, K. R.
    Stovall, S.
    Marcott, V.
    Gan, B.
    Bird, S.
    Wang, X.
    Do, K. A.
    Altamirano, P. F.
    Zurita, A. J.
    Doyle, L. A.
    Lara, P. N., Jr.
    Tannir, N. M.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 804 - 808
12345